NC
PDSB icon

NewSquare Capital’s PDS Biotechnology PDSB Stock Holding History

NewSquare Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$1.01K – 814
2023
Q2 		$1.01K Hold
200
– – ﹤0.01% 609
2023
Q1 		$1.23K Hold
200
– – ﹤0.01% 628
2022
Q4 		$2.64K Buy
+200
New +$1.41K ﹤0.01% 449

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewSquare Capital's PDSB Position: Q3 2023 in Review

NewSquare Capital sold out of PDS Biotechnology (PDSB) in Q3 2023, closing a stake of 200 shares — an estimated $1.01K sold.

NewSquare Capital first reported a position in PDSB in Q4 2022 and held it in 3 quarters. The position peaked at $2.64K in Q4 2022. 78 funds tracked by Wall St. Rank hold PDSB as of Q3 2023.

  • NewSquare Capital reported no remaining PDS Biotechnology position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 200 PDS Biotechnology shares in Q3 2023, an estimated $1.01K.
  • NewSquare Capital first reported a position in PDS Biotechnology in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's PDS Biotechnology position peaked at $2.64K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.